1 SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations

2 Compared with COVID-19 Vaccine Efficacy Estimates Against Symptomatic

3 Infection

4 Amy J. Schuh¹, Panayampalli S. Satheshkumar¹, Stephanie Dietz¹, Lara Bull-Otterson¹, Myrna Charles¹,
 5 Chris Edens¹, Jefferson M. Jones¹, Kristina L. Bajema¹, Kristie E.N. Clarke¹, L. Clifford McDonald¹,
 6 Sadhna Patel¹, Kendra Cuffe¹, Natalie J. Thornburg¹, Jarad Schiffer¹, Kelly Chun², Monique Bastidas²,
 7 Manory Fernando², Christos J. Petropoulos², Terri Wrin², Suqin Cai², Dot Adcock², Deborah Sesok-
 8 Pizzini², Stanley Letovsky², Alicia M. Fry¹, Aron J. Hall¹, Adi V. Gundlapalli¹

9 ¹CDC COVID-19 Response, United States Centers for Disease Control and Prevention, Atlanta, GA

10 ²Labcorp, Burlington, NC

11 **Running title:** Convalescent sera antibody levels compared to vaccine efficacy estimates

12 **Abstract word count:** 172

13 **Text word count:** 3,282

14 **Footnotes**

15 ¹Potential conflicts of interest have been disclosed within the ICMJE Disclosure Forms.

16 ²This work was supported by the United States Centers for Disease Control and Prevention.

17 ³This work has not been presented at any national or international meeting.

18 ⁴Correspondence: Adi V. Gundlapalli, MD, PhD, Center for Surveillance, Epidemiology, and
19 Laboratory Services, United States Centers for Disease Control and Prevention, Atlanta, Georgia,
20 30333; agundlapalli@cdc.gov

21 ABSTRACT

22 Previous vaccine efficacy (VE) studies have estimated neutralizing and binding antibody
 23 concentrations that correlate with protection from symptomatic infection; how these estimates compare
 24 to those generated in response to SARS-CoV-2 infection is unclear. Here, we assessed quantitative
 25 neutralizing and binding antibody concentrations using standardized SARS-CoV-2 assays on 3,067
 26 serum specimens collected during July 27, 2020-August 27, 2020 from COVID-19 unvaccinated persons
 27 with detectable anti-SARS-CoV-2 antibodies using qualitative antibody assays. Quantitative neutralizing
 28 and binding antibody concentrations were strongly positively correlated ($r=0.76$, $p<0.0001$) and were
 29 noted to be several fold lower in the unvaccinated study population as compared to published data on
 30 concentrations noted 28 days post-vaccination. In this convenience sample, ~88% of neutralizing and
 31 ~63-86% of binding antibody concentrations met or exceeded concentrations associated with 70%
 32 COVID-19 VE against symptomatic infection from published VE studies; ~30% of neutralizing and 1-
 33 14% of binding antibody concentrations met or exceeded concentrations associated with 90% COVID-
 34 19 VE. These data support observations of infection-induced immunity and current recommendations
 35 for vaccination post infection to maximize protection against symptomatic COVID-19.

36
 37 **Keywords:** SARS-CoV-2, COVID-19, quantitative anti-SARS-CoV-2 IgG, neutralizing antibodies,
 38 correlation, antibody, immune, protection, correlate of protection

39 BACKGROUND

40 As of October 18, 2021, 66.7% of the US population 12 years of age and older has been fully
 41 vaccinated for COVID-19 [1]. A recent Gallup survey found that 18% of Americans would not agree to
 42 be vaccinated if a US Food and Drug Administration (FDA)-approved COVID-19 vaccine were
 43 available to them immediately at no cost [2]. One of the primary reasons cited for vaccine hesitancy was
 44 a history of SARS-CoV-2 infection and resultant antibodies.

45 Cumulative evidence indicates that SARS-CoV-2 antibodies are protective against SARS-CoV-2 re-
 46 infection [3]. A series of non-human primate challenge studies demonstrated the central role of SARS-
 47 CoV-2 neutralizing antibodies in protection from re-infection [4-6]. A randomized clinical trial
 48 involving the subcutaneous administration of REGEN-COV, a combination of two SARS-CoV-2
 49 neutralizing monoclonal antibodies, or placebo within 96 hours of SARS-CoV-2 exposure demonstrated
 50 that REGEN-COV prevented symptomatic COVID-19 and asymptomatic SARS-CoV-2 infection [7]. A
 51 longitudinal study of >12,000 health care workers showed that SARS-CoV-2 infection-induced
 52 protective immunity lasts for at least 6 months [8].

53 The establishment of the First World Health Organization (WHO) International Standard for Anti-
 54 SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody
 55 concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and
 56 propose standardized immune correlates of protection against symptomatic infection (or risk of
 57 symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose
 58 series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1)
 59 vaccines OR 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen [JNJ-78436735]
 60 vaccine) across vaccine trials that have used different antibody assays. Comparing antibody
 61 concentrations of unvaccinated persons with anti-SARS-CoV-2 antibodies to COVID-19 vaccinated
 62 cohorts and to estimated antibody concentrations associated with COVID-19 vaccine effectiveness

would accomplish three goals: 1) improve understanding of the population distribution of antibody concentrations in response to infection and vaccination, 2) help establish relationship of quantitative antibody levels to those associated with protection against illness from published studies, and 3) inform better targeted messaging for universal COVID-19 vaccination.

Numerous SARS-CoV-2 serological assays have been developed over the course of the COVID-19 pandemic to measure virus-specific antibody responses [14]. Persons who recover from SARS-CoV-2 infection or receive a COVID-19 vaccine typically develop virus-specific neutralizing antibodies, with most of these antibodies directed against the immunodominant receptor binding domain (RBD) of the spike (S) protein [15, 16]. Efficacy trials of the ChAdOx1 [11] and mRNA-1273 [12] vaccines showed that higher anti-SARS-CoV-2 S IgG, anti-SARS-CoV-2 RBD IgG, and SARS-CoV-2 neutralizing antibody concentrations were correlated with a reduced risk of symptomatic infection. Both trials determined antibody concentrations associated with varying levels of VE against symptomatic COVID-19 [11, 12]. The ChAdOx1 vaccine trial estimated that 70% and 90% VE against symptomatic COVID-19 was associated with 50% neutralizing antibody titer (NT_{50}) concentrations of 3.7 and 64.1 international units per mL (IU/mL), respectively, and 70% and 90% VE was associated with anti-RBD IgG antibodies concentrations of 165.0 and 2360.0 binding antibody units per mL (BAU/mL), respectively [11]. The mRNA-1273 vaccine trial estimated that 70% and 90% VE against symptomatic COVID-19 was associated with NT_{50} concentrations of 4.0 and 83.0 IU/mL, respectively, and 70% and 90% VE was associated with anti-RBD IgG antibodies concentrations of 8.0 and 775.0 BAU/mL, respectively [12]. However, it remains unclear how these antibody concentrations compare to those generated in response to SARS-CoV-2 infection in COVID-19 unvaccinated persons. To answer this question, we tested 3,067 pre-vaccination sera collected as part of a nationwide commercial laboratory seroprevalence study led by the US Centers for Disease Control and Prevention (CDC) [17] that had previously tested positive for anti-SARS-CoV-2 antibodies using standardized anti-SARS-CoV-2 RBD

IgG and SARS-CoV-2 pseudovirus neutralization antibody assays, and then compared these antibody concentrations to concentrations measured in COVID-19 vaccinated cohorts (28 days post-vaccination) and to those associated with 70% and 90% COVID-19 VE against symptomatic infection for two of the vaccines for which such data are published to date.

METHODS

Specimen Source and Study Design

Sera were collected by two US-based commercial laboratories for routine or acute clinical care (e.g., cholesterol screening or a sick visit) as part of a nationwide seroprevalence study; detailed methods have previously been described [17]. Briefly, blood specimens collected for COVID-19-related reasons were excluded. Sera were tested [17] for anti-SARS-CoV-2 antibodies using one of the following three qualitative assays issued emergency use authorization by the FDA that were in use in the clinical laboratories: 1) Architect™ SARS-CoV-2 IgG Assay (nucleocapsid (N) protein; Abbott, Chicago, IL), 2) VITROS® Anti-SARS-CoV-2 IgG Assay (S protein; Ortho-Clinical Diagnostics, Raritan, NJ), and 3) Elecsys® Anti-SARS-CoV-2 Assay (N protein; Roche, Indianapolis, IN) (Supplementary figure 3). Among 84,683 total serum samples collected during July 27, 2020-August 27, 2020 identified as anti-SARS-CoV-2 antibody positive and had linked age and sex information (as part of the larger serosurveillance study) [17], 3067 serum specimens were selected by convenience sampling for reflex testing with anti-SARS-CoV-2 quantitative IgG and neutralizing antibody assays. Data on race, ethnicity, and occurrence or date of SARS-CoV-2 infection or symptoms were not available; data on prior SARS-CoV-2 quantitative reverse transcription polymerase chain reaction qRT-PCR test results were not available for most persons.

108 **Ethics**

109 This activity was reviewed by CDC and was conducted consistent with applicable federal law and
110 CDC policy (45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44
111 U.S.C. Sect. 3501 et seq.). Informed consent was waived, as all data were deidentified.

112 **PhenoSense® CoV Neutralizing Antibody Assay**

113 Neutralizing antibodies against the SARS-CoV-2 S protein were measured using the PhenoSense
114 CoV Neutralizing Antibody Assay® [18]. To measure SARS-CoV-2 neutralizing antibodies, human
115 immunodeficiency virus-1 pseudovirions expressing the SARS-CoV-2 S protein were prepared by co-
116 transfecting HEK293 producer cells with an HIV-1 genomic vector and a SARS-CoV-2 envelope
117 protein expression vector. Serial dilutions of sera were incubated with recombinant pseudovirions and
118 neutralizing activity was assessed by measuring the inhibition of luciferase activity in HEK293 target
119 cells co-expressing the angiotensin-converting enzyme 2 and transmembrane serine protease 2 receptors.
120 Fifty percent neutralizing antibody titers (NT₅₀) were expressed as the reciprocal of the serum dilution
121 conferring 50% inhibition of pseudovirus infection. Calibration of the PhenoSense CoV Neutralizing
122 Antibody Assay® with the First WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin
123 (20/136, National Institute for Biological Standards and Controls, UK) [9] allowed us to generate a
124 calibration factor of 0.0653 (S protein containing G614) and convert NT₅₀ values from titers to
125 international units per mL (IU/mL) by multiplying by the calibration factor .

126 **Cov2Quant IgG® Assay**

127 Anti-SARS-CoV-2 RBD IgG in sera were quantified using the electrochemiluminescent (ECL)
128 Cov2Quant IgG® Assay [19]. Briefly, sera were incubated with biotin-conjugated, recombinant SARS-
129 CoV-2 RBD antigen bound to a streptavidin, carbon-coated microtiter well plate. After washing the
130 plate, the wells were incubated with ruthenium-conjugated anti-IgG and a final wash was performed to
131 remove unbound material. Voltage was applied to the metallic electrode on the base of the plate and a

photomultiplier was used to measure the ECL signal generated from each well. The signal in relative light units (RLU) is directly proportional to the anti-RBD IgG concentration in sera. Each assay batch included a dilution series of affinity-purified human IgG standard that was used to calculate the anti-SARS-CoV-2 RBD IgG concentration of each serum. Calibration of the Cov2Quant IgG® Assay with the WHO International Standard allowed us to generate a calibration factor of 25 and convert anti-SARS-CoV-2 RBD IgG concentrations from $\mu\text{g/mL}$ to binding antibody units per mL (BAU/mL) by multiplying by the calibration factor.

Comparison of Study Antibody Data to Antibody Concentrations Associated with COVID-19 VE

Of the COVID-19 vaccines in use around the world currently, serological correlates of protection thresholds associated with VE have been estimated for ChAdOx1 [11] and mRNA-1273 [12] using the First WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin. As the quantitative antibody assays used in our study were calibrated to the same standard, we were able to compare antibody concentrations in our study to those estimated to be associated with 70% and 90% COVID-19 VE to ChAdOx1 and mRNA-1273.

Statistical Analyses

Data management tasks, and statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC) and GraphPad Prism 9.0.0 (GraphPad Software, San Diego, CA). T-tests on $\log_{10}$ -transformed data were used to determine if there were statistically significant differences between geometric mean anti-SARS-CoV-2 RBD IgG and NT_{50} concentrations by sex. ANOVAs on $\log_{10}$ -transformed data were used to determine if there were statistically significant differences between geometric mean anti-SARS-CoV-2 RBD IgG and NT_{50} concentration according to previous qualitative antibody test and age category. Post-hoc Tukey's tests were performed to identify previous qualitative antibody tests and age categories with significantly different anti-SARS-CoV-2 RBD IgG and NT_{50} concentrations; p-values were adjusted to account for multiple comparisons. Pearson's correlation was

used to assess the overall relationship between $\log_{10}$ anti-RBD IgG and $\log_{10}$ NT₅₀ concentrations, as well as the relationships between the two variables across sex and age category. Two-sided p-values <0.05 were considered statistically significant.

RESULTS

Of the overall convenience sample of 3,067 serum specimens collected during July 27, 2020-August 27, 2020 with detectable anti-SARS-CoV-2 antibodies on a qualitative assay, 1,309 were from males (42.7%) and 1,758 (57.3%) were from females, 779 (25.4%) were from persons aged <18 years, 982 (32.0%) were from persons aged 18–49 years, 798 (26.0%) were from persons aged 50–64 years, and 508 (16.6%) were from persons aged ≥65 years.

Most of the serum specimens (n=2568, 83.7%) tested positive for both quantitative SARS-CoV-2 neutralizing antibodies and quantitative anti-SARS-CoV-2 RBD IgG; 271 sera (8.8%) tested negative for both neutralizing antibodies and anti-RBD IgG, 83 sera (2.7%) tested negative for neutralizing antibodies only, and 145 sera (4.7%) tested negative for anti-RBD IgG only. Geometric mean NT₅₀ concentrations differed significantly according to the qualitative antibody test type that was used to screen sera for study inclusion (p<0.0001; Supplementary Figure 4A), while geometric mean anti-RBD IgG concentrations did not differ significantly according to the qualitative antibody test type that was used to screen sera for study inclusion (p=0.02998; Supplementary Figure 4B).

The overall geometric mean NT₅₀ concentration was 28.8 IU/mL (95% confidence interval (CI): 26.8, 31.0) and did not differ significantly according to sex (male: 30.9 IU/mL, 95% CI: 27.4, 34.8; female: 27.3 IU/mL, 95% CI: 25.0, 30.0; p=0.1088) but differed significantly according to age category (<18 years: 31.3 IU/mL, 95% CI: 28.4, 34.6; 18–49 years: 23.1 IU/mL, 95% CI: 20.3, 26.2; 50–64 years: 38.0 IU/mL, 95% CI: 32.5, 44.4; ≥65 years: 25.0 IU/mL, 95% CI: 20, 31.3; p<0.0001; Figure 1A). Persons aged <18 years had significantly higher NT₅₀ concentrations compared to persons aged 18–49 years (p=0.0108), and persons aged 50–64 years had significantly higher NT₅₀ concentrations

180 compared to persons aged 18–49 years ($p<0.0001$) and persons aged ≥ 65 years ($p=0.0020$) (Figure 1A).
 181 The overall geometric mean anti-RBD IgG concentration was 162.5 BAU/mL (95% CI: 152.9, 172.7)
 182 and did not differ significantly according to sex (male: 171.3 BAU/mL, 95% CI: 155.6, 188.5; female:
 183 156.3 BAU/mL, 95% CI: 144.4, 169.1; $p=0.1447$) but did differ significantly according to age category
 184 (<18 years: 218.2 BAU/mL, 95% CI: 199.2, 239.1; 18–49 years: 122.2 BAU/mL, 95% CI: 109.8, 136.1;
 185 50–64 years: 189.0 BAU/mL, 95% CI: 167.2, 213.7; ≥ 65 years: 141.4 BAU/mL, 95% CI: 117.8, 169.8;
 186 $p<0.0001$; Figure 1B). Like the age-associated patterns of neutralizing antibody concentrations, persons
 187 aged <18 years had significantly higher anti-RBD IgG concentrations compared to persons aged 18–49
 188 years ($p<0.0001$) and persons aged ≥ 65 years ($p<0.0001$), and persons aged 50–64 years had
 189 significantly higher anti-RBD IgG concentrations compared to persons aged 18–49 years ($p<0.0001$)
 190 and persons aged ≥ 65 years ($p=0.0147$) (Figure 1B).

191 We found an overall significant, strong positive correlation between NT₅₀ concentrations and anti-
 192 RBD IgG concentrations ($r=0.76$, $p<0.0001$; Figure 1A). The strength of the relationship remained
 193 consistent across sex (male: $r=0.76$, $p<0.0001$; female: $r=0.76$, $p<0.0001$; Figure 1B) and increased with
 194 increasing age category (<18 years: $r=0.67$, $p<0.0001$; 18–49 years: $r=0.69$, $p<0.0001$; 50–64 years:
 195 $r=0.79$, $p<0.0001$; ≥ 65 years: $r=0.88$, $p<0.0001$; Figure 2).

196 NT₅₀ concentrations in the overall convenience sample of 3,067 serum specimens collected during
 197 July 27, 2020–August 27, 2020 with detectable anti-SARS-CoV-2 antibodies on a qualitative assay were
 198 2.7-fold lower and 8.6-fold lower than concentrations reported from serum specimens collected 28 days
 199 post COVID-19 vaccination from ChAdOx1 [11] and mRNA-1273 [12] VE study participants classified
 200 as not having COVID-19 during the follow-up period, respectively (Figures 3A and B). Likewise, anti-
 201 RBD IgG concentrations in the overall convenience sample were 1.5-fold lower and 24.2-fold lower
 202 than concentrations reported from serum specimens collected 28 days post COVID-19 vaccination from
 203 ChAdOx1 and mRNA-1273 VE study participants classified as not having COVID-19 during the

follow-up period, respectively (Figure 3C and D). Overall, 88.3% of serum specimens in this study met or exceeded the concentration of SARS-CoV-2 neutralizing antibodies associated with 70% ChAdOx1 and mRNA-1273 VE, while 32.9% and 27.1% of sera met or exceeded the concentration of SARS-CoV-2 neutralizing antibodies associated with 90% ChAdOx1 and mRNA-1273 VE, respectively (Figure 1A). For binding antibodies, we found that 63.1% and 86.4% of serum specimens from this study met or exceeded the concentration of anti-RBD IgG antibodies associated with 70% ChAdOx1 and mRNA-1273 VE, respectively, and 1.3% and 13.6% of sera met or exceeded the concentration of anti-RBD IgG antibodies associated with 90% ChAdOx1 and mRNA-1273 VE, respectively (Figure 1B). A greater percentage of males and persons aged ≥ 50 years met or exceeded the concentrations of SARS-CoV-2 neutralizing antibodies and anti-RBD Ig associated with 70% ChAdOx1 and mRNA-1273 VE than females and persons aged < 50 years, respectively.

DISCUSSION

Similar to the ChAdOx1 [11] and mRNA-1273 [12] VE trial serologic testing results reported in the literature, we demonstrate a statistically significant, strong positive correlation between standardized anti-SARS-CoV-2 RBD IgG and SARS-CoV-2 NT₅₀ concentrations, across all sex and age categories, using sera from unvaccinated persons with previous SARS-CoV-2 infection. Based on these broad correlations, our results suggest that high-throughput, quantitative anti-SARS-CoV-2 RBD IgG assays can be used as surrogates for SARS-CoV-2 pseudovirus neutralization assays that are considered mechanistic correlates of protection [12]. Performing high-throughput, commercially available quantitative IgG assays is logistically feasible and practical on a large scale compared to performing time- and resource-intensive neutralization assays. Thus, there is a continued need for FDA-approved quantitative anti-SARS-CoV-2 S and RBD IgG assays in the management of the pandemic to facilitate assessment of antibody concentrations associated with protection from infection and/or disease [14].

While our finding that most serum specimens in this study met or exceeded antibody concentrations associated with 70% COVID VE estimates support the real-world observations of infection-induced immunity from re-infection, it is important to note that less than 33% of sera from unvaccinated persons with previous SARS-CoV-2 infection met or exceeded antibody concentrations associated with 90% ChAdOx1 and mRNA-1273 vaccine efficacy. This suggests that not all persons with a history of SARS-CoV-2 infection generate antibody responses of sufficient magnitude, as measured by a single, randomly timed blood test, to protect them against symptomatic re-infection. In addition to the circulation of the hyper-transmissible Delta variant of SARS-CoV-2, this finding may also partially explain the rise in COVID-19 cases that occurred in the United States in August 2021 despite a national serosurvey in May 2021 showing that 83.3% of the population had SARS-CoV-2 infection- and/or vaccine-induced antibodies [20]. Meanwhile, at least in the short-term (28 days), COVID-19 vaccination can provide 2.7 to 8.6-fold higher neutralizing antibody concentrations and 1.5 to 24.2-fold higher binding antibody concentrations. Thus, our results support current guidance that all eligible persons should consider COVID-19 vaccination to maximize their protection against symptomatic COVID-19 regardless of their SARS-CoV-2 infection history.

Our sampling approach of selecting specimens identified as positive using at least one qualitative anti-SARS-CoV-2 antibody assay would have selected for persons who had more severe disease and thus higher antibody concentrations, and/or in whom antibodies had not waned. This selection bias may have led us to overestimate the percentage of persons with antibody concentrations meeting or exceeding those concentrations associated with 70% and 90% COVID-19 VE and would have missed persons infected with SARS-CoV-2 who did not mount a measurable post-infection immune response or had antibodies below detectable levels.

Our study has several limitations. First, due to the absence of information on whether persons had symptoms or if testing had been done or, if so, the date of COVID-19 symptom onset and/or a positive

251 SARS-CoV-2 qRT-PCR or antigen test, we were unable to calculate the number of days that had elapsed
 252 between infection and collection of serum for antibody testing and thus the measurements might not
 253 reflect peak antibody concentrations. The ChAdOx1 and mRNA-1273 VE trials measured serum
 254 antibody concentrations 28 days after the second vaccine dose, presumably at the peak of the measurable
 255 humoral immune response to the vaccine. Therefore, if the sera used in this study were collected >28
 256 days after SARS-CoV-2 infection, it is possible that the percentage of persons with antibody
 257 concentrations meeting or exceeding those concentrations associated with 70% and 90% COVID-19 VE
 258 were underestimated. However, as a result of the sharp rise in COVID-19 cases in the United States in
 259 mid-June 2020 (Supplementary Figure 2) [21], >50% of cases reported in the country prior to July 27,
 260 2020 (date first specimens used in this study were collected) occurred after June 15, 2020. This indicates
 261 that the majority of sera in this study were likely to have been collected within 73 days of SARS-CoV-2
 262 infection, a time before IgG antibody concentrations would be expected to have significantly waned
 263 from peak post-infection levels [22].

264 Second, 13.6% of persons had anti-RBD IgG concentrations below the cutoff value of the assay
 265 (37.5 BAU/mL). However, the anti-RBD IgG concentration associated with 70% mRNA-1273 VE (8.0
 266 BAU/mL) is below the cutoff value of the Cov2Quant IgG® Assay used in this study. Therefore, it is
 267 possible that some persons below the assay cutoff value might have had anti-RBD IgG concentrations
 268 greater than or equal to 8.0 BAU/mL, leading us to underestimate the percentage of persons with
 269 antibody concentrations meeting or exceeding those concentrations associated with 70% mRNA-1274
 270 COVID-19 VE.

271 Third, extrapolating these population-level results to individual-level clinical decision making with
 272 regard to immune protection based on a single antibody test poses a challenge. The sera tested here were
 273 untimed with regard to onset of infection and we have no knowledge of the immune status of the
 274 individuals in terms of co-morbidities and medications. These challenges are also applicable to post-

275 vaccination sera in terms of certain populations responding less well to vaccines in terms of neutralizing
276 and binding antibodies as compared to healthy volunteers in vaccine trials and limited availability of
277 standardized quantitative assays [3].

278 Fourth, our findings, as well as the timing of the ChAdOx1 CoV-19 and mRNA-1273 VE trials,
279 predate the circulation of the Delta variant of SARS-CoV-2 that exhibits a decreased sensitivity to post-
280 vaccination antibody neutralization compared to the Alpha variant of the virus [23]. Therefore, our data
281 is not able to address potential protection of persons infected SARS-CoV-2 in mid-2020 against
282 infection with the Delta variant of the virus.

283 Finally, the efficiency and redundancy of the immune system, especially for the prevention of severe
284 disease, in terms of humoral [12], cellular immunity, memory and anamnestic response on second
285 exposure to SARS-CoV-2 likely contribute to protection beyond an estimate indicated solely by single
286 antibody concentrations [6, 24].

287 In conclusion, we demonstrate that in this sample, most non-vaccinated persons with qualitative
288 antibody evidence of prior infection had quantitative antibody concentrations against SARS-CoV-2 that
289 met or exceeded antibody levels associated with 70% VE. However, only a small proportion had
290 antibody responses that met or exceeded levels associated with 90% VE. Our findings suggest that
291 persons with a prior COVID-19 would benefit from vaccination to maximize protective antibody
292 concentrations against symptomatic COVID-19.

293 **Notes**

294 ***Acknowledgments.*** The authors thank Marla Williams, Morgan Herle, Wade Tanico, and Paul Theobald
 295 from Labcorp for help received in planning and execution of sample logistics and data acquisition. A
 296 special thanks goes to the reference laboratory operators that performed Cov2Quant IgG® and
 297 PhenoSense® CoV Neutralizing Antibody assays. We also thank members of the Multistate Assessment
 298 of SARS-CoV-2 Seroprevalence (MASS) steering group, including Lyle Peterson, Margaret Honein,
 299 Adam MacNeil, Eduardo Azziz-Baumgartner, Francisco Averhoff, Sridhar Basavaraju, Tina Benoit,
 300 Carla Black, Kevin Berney, Ryan Weigand, Michele Owen, Ruchi Pancholy, and Lisa Grohskopf.

301 ***Disclaimer.*** The findings and conclusions in this report are those of the authors and do not necessarily
 302 represent the official position of the Centers for Disease Control and Prevention.

303 ***Financial support.*** This work was supported by the United States Centers for Disease Control and
 304 Prevention, Atlanta, Georgia.

REFERENCES

1. US Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States. Available at: https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total. Accessed October 14, 2021.
2. Jones JM. About One in Five Americans Remain Vaccine-Resistant. Available at: <https://news.gallup.com/poll/353081/one-five-americans-remain-vaccine-resistant.aspx>. Accessed September 12, 2021.
3. US Centers for Disease Control and Prevention. Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine-induced-immunity.html>. Accessed November 5, 2021 2021.
4. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science* **2020**; 369:812-7.
5. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature* **2021**; 590:630-4.
6. Corbett KS, Nason MC, Flach B, et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. *Science* **2021**; 373:eabj0299.
7. O'Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. *N Engl J Med* **2021**; 385:1184-95.
8. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J Med* **2021**; 384:533-40.
9. Mattiuzzo G, Bentley EM, Hassall M, et al. Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody (WHO/BS/2020/2403): World Health Organization, **2020**.

- 328 10. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate
329 for COVID-19 vaccines. *Vaccine* **2021**; 39:4423-8.
- 330 11. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic
331 SARS-CoV-2 infection. *medRxiv* **2021**.
- 332 12. Gilbert PB, Montefiori DC, McDermott A, et al. Immune Correlates Analysis of the mRNA-1273
333 COVID-19 Vaccine Efficacy Trial. *medRxiv* **2021**.
- 334 13. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of
335 immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* **2021**; 27:1205-11.
- 336 14. Gundlapalli AV, Salerno RM, Brooks JT, et al. SARS-CoV-2 Serologic Assay Needs for the Next
337 Phase of the US COVID-19 Pandemic Response. *Open Forum Infect Dis* **2021**; 8:ofaa555.
- 338 15. Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*
339 **2020**; 584:115-9.
- 340 16. Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in
341 convalescent individuals. *Nature* **2020**; 584:437-42.
- 342 17. Bajema KL, Wiegand RE, Cuffe K, et al. Estimated SARS-CoV-2 Seroprevalence in the US as of
343 September 2020. *JAMA Intern Med* **2021**; 181:450-60.
- 344 18. Markmann AJ, Giallourou N, Bhowmik DR, et al. Sex disparities and neutralizing antibody
345 durability to SARS-CoV-2 infection in convalescent individuals. *medRxiv* **2021**.
- 346 19. Kappelman MD, Weaver KN, Boccieri M, et al. Humoral Immune Response to Messenger RNA
347 COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease. *Gastroenterology* **2021**.
- 348 20. Jones JM, Stone M, Sulaeman H, et al. Estimated US Infection- and Vaccine-Induced SARS-CoV-2
349 Seroprevalence Based on Blood Donations, July 2020-May 2021. *JAMA* **2021**.

- 350 21. US Centers for Disease Control and Prevention. Trends in Number of COVID-19 Cases and Deaths
351 in the US Reported to CDC, by State/Territory. Available at: [https://covid.cdc.gov/covid-data-](https://covid.cdc.gov/covid-data-tracker/#trends_dailycases)
352 [tracker/#trends_dailycases](https://covid.cdc.gov/covid-data-tracker/#trends_dailycases). Accessed October 14, 2021.
- 353 22. Egbert ER, Xiao S, Colantuoni E, et al. Durability of Spike Immunoglobulin G Antibodies to SARS-
354 CoV-2 Among Health Care Workers With Prior Infection. JAMA Netw Open **2021**; 4:e2123256.
- 355 23. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to
356 antibody neutralization. Nature **2021**; 596:276-80.
- 357 24. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell **2021**; 184:861-80.

Figure 1. SARS-CoV-2 50% neutralizing antibody titer (NT₅₀) concentrations and anti-SARS-CoV-2 receptor binding domain (RBD) IgG concentrations for the overall convenience sample of 3,067 serum specimens collected during July 27,2020-August 27, 2020 with detectable anti-SARS-CoV-2 antibodies on a qualitative assay, and according to sex and age category. A) SARS-CoV-2 NT₅₀ concentrations in international units per mL (IU/mL) and B) Anti-SARS-CoV-2 RBD IgG concentrations in binding antibody units per mL (BAU/mL). Horizontal bars represent geometric means, vertical error bars represent 95% confidence intervals, and dashed horizontal lines represent assay cut-off values for seropositivity. P-values from t-tests (sex) and post-hoc Tukey tests (age class) are shown for each sex and age class comparison. Bolded p-values denote statistical significance (p<0.05). Dotted horizontal lines represent antibody concentrations associated with 70% and 90% ChAdOx1 [11] and mRNA-1273 [12] vaccine efficacy (VE). The percentage of sera with antibody concentrations that meet or exceed the concentrations represented by each of the horizontal dotted lines are shown below the charts.

Figure 2. Correlations between SARS-CoV-2 50% neutralizing antibody titer (NT₅₀) concentrations in international units per mL (IU/mL) and anti-SARS-CoV-2 receptor binding domain (RBD) IgG concentrations in binding antibody units per mL (BAU/mL) for the convenience sample of 3,067 serum specimens collected during July 27,2020-August 27, 2020 with detectable anti-SARS-CoV-2 antibodies on a qualitative assay. A) Overall, B) by sex, and C) by age class.

Figure 3. SARS-CoV-2 50% neutralizing antibody titer (NT₅₀) concentrations in international units per mL (IU/mL) and anti-SARS-CoV-2 receptor binding domain (RBD) IgG concentrations in binding antibody units per mL (BAU/mL) for the overall convenience sample of 3,067 serum specimens collected during July 27,2020-August 27, 2020 with detectable anti-SARS-CoV-2 antibodies on a qualitative assay compared to 28 days post COVID-19 vaccination concentrations in ChAdOx1 [11] and mRNA-1273 [12] VE study participants classified as not having COVID-19 during the follow-up period. A) Median and interquartile range SARS-CoV-2 NT₅₀ concentrations for the overall convenience

382 sample compared to concentrations in VE study participants who received the ChAdOx1 vaccine and
383 were classified as not having COVID-19 during the follow-up period, B) Geometric mean and 95%
384 confidence interval SARS-CoV-2 NT₅₀ concentrations for the overall convenience sample compared to
385 concentrations in VE study participants who received the mRNA-1273 vaccine and were classified as
386 not having COVID-19 during the follow-up period, C) Median and interquartile range anti-SARS-CoV-
387 2 RBD IgG concentrations for the overall convenience sample compared to concentrations in VE study
388 participants who received the ChAdOx1 vaccine and were classified as not having COVID-19 during the
389 follow-up period, and D) Geometric mean and 95% CI anti-SARS-CoV-2 RBD IgG concentrations for
390 the overall convenience sample compared to concentrations in VE study participants who received the
391 mRNA-1273 vaccine and were classified as not having COVID-19 during the follow-up period.
392 Horizontal bars represent medians or geometric means, and vertical error bars represent the interquartile
393 range surrounding the median or 95% confidence intervals surrounding the geometric mean.

A

B

A

• Overall ($r=0.76$, $p<0.0001$)

B

• Male ($r=0.76$, $p<0.0001$)

• Female ($r=0.76$, $p<0.0001$)

C

• <18 ($r=0.67$, $p<0.0001$)

• 18—49 ($r=0.69$, $p<0.0001$)

• 50—64 ($r=0.79$, $p<0.0001$)

• >65 ($r=0.88$, $p<0.0001$)